Global Gonorrhea Therapeutics Market 2017-2021

  • ID: 4417880
  • Report
  • Region: Global
  • 79 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Alopexx Pharmaceuticals
  • AstraZeneca
  • Bharat Pharmaceuticals
  • Cempra
  • Debiopharm Group
  • GlaxoSmithKline
  • MORE
About Gonorrhea Therapeutics

Gonorrhea is a sexually transmitted disease (STD) that affects both men and women. The infection affects the genitals, rectum, and the throat. The treatment landscape typically involves the use of antibiotics with dual therapy dominating the market compared with monotherapy. As the market has a deep penetration of generics, the growth rate is expected to be moderate during the forecast period. Additionally, the advent of new antibiotic-resistant strains will continue to hinder the growth prospects.

The analysts forecast the global gonorrhea therapeutics market to grow at a CAGR of 2.88% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global gonorrhea therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Gonorrhea Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bharat Pharmaceuticals
  • GlaxoSmithKline
  • Merck
  • Pfizer
Other prominent vendors
  • Alopexx Pharmaceuticals
  • AstraZeneca
  • Cempra
  • Debiopharm Group
  • Melinta Therapeutics
Market drivers
  • Rising prevalence of disease
  • For a full, detailed list, view the full report
Market challenges
  • Emergence of antibiotic-resistant gonococcal strain
  • For a full, detailed list, view the full report
Market trends
  • Advent of vaccine for prevention of gonorrhea
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alopexx Pharmaceuticals
  • AstraZeneca
  • Bharat Pharmaceuticals
  • Cempra
  • Debiopharm Group
  • GlaxoSmithKline
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
  • Market outline
PART 05: GONORRHEA: A BRIEF INTRODUCTION
  • What is gonorrhea?
  • What causes gonorrhea?
  • What are the various symptoms of gonorrhea?
  • How is gonorrhea treated?
PART 06: MARKET LANDSCAPE
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: PIPELINE

PART 08: MARKET SEGMENTATION BY APPLICATION
  • Monotherapy
  • Market size and forecast
  • Dual therapy
  • Market size and forecast
PART 09: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast
  • EMEA - Market size and forecast
  • APAC - Market size and forecast
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Rising government initiatives to combat antibiotic resistance
  • Advent of vaccine for prevention of gonorrhea
  • Expedited Partner Therapy (EPT)
PART 13: VENDOR LANDSCAPE
  • Competitive landscape
PART 14: KEY VENDOR ANALYSIS
  • Bharat Pharmaceuticals
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Other prominent vendors
PART 15: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Incidence rate of gonorrhea in US, 2008 (per 100,000 population)
Exhibit 02: Symptoms of gonorrhea
Exhibit 03: Global gonorrhea therapeutics market: Snapshot
Exhibit 04: Global gonorrhea therapeutics market, 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis of global gonorrhea therapeutics market
Exhibit 06: Five forces analysis
Exhibit 07: Key clinical trials
Exhibit 08: Global gonorrhea therapeutics market: Segmentation by application
Exhibit 09: Global gonorrhea therapeutics market share by application, 2016
Exhibit 10: Global gonorrhea monotherapy therapeutics market, 2016-2021 ($ millions)
Exhibit 11: Global gonorrhea dual therapy therapeutics market, 2016-2021 ($ millions)
Exhibit 12: Global gonorrhea therapeutics market share by region, 2016 and 2021
Exhibit 13: Global gonorrhea therapeutics market revenue by region, 2016-2021 ($ millions)
Exhibit 14: Global gonorrhea therapeutics market share by region, 2016-2021
Exhibit 15: Regional comparison
Exhibit 16: Gonorrhea therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 17: Gonorrhea therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 18: Gonorrhea therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 19: Key leading countries
Exhibit 20: Travel associated gonorrhea cases by region, 2008-2013
Exhibit 21: Prevalence rate of gonorrhea, 2009
Exhibit 22: Prevalence rate of gonorrhea by age and race
Exhibit 23: Infertility ratio in males and females
Exhibit 24: Revenue history for Zithromax/Zmax, 2005-2016
Exhibit 25: Pictorial presentation of EPT
Exhibit 26: Competitive structure analysis of global antibiotics market 2016
Exhibit 27: Bharat Pharmaceuticals: Strength assessment
Exhibit 28: Bharat Pharmaceuticals: Strategy assessment
Exhibit 29: Bharat Pharmaceuticals: Opportunity assessment
Exhibit 30: GlaxoSmithKline: Key highlights
Exhibit 31: GlaxoSmithKline: Strength assessment
Exhibit 32: GlaxoSmithKline: Strategy assessment
Exhibit 33: GlaxoSmithKline: Opportunity assessment
Exhibit 34: Merck: Key highlights
Exhibit 35: Merck: Strength assessment
Exhibit 36: Merck: Strategy assessment
Exhibit 37: Merck: Opportunity assessment
Exhibit 38: Pfizer: Key highlights
Exhibit 39: Pfizer: Strength assessment
Exhibit 40: Pfizer: Strategy assessment
Exhibit 41: Pfizer: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Alopexx Pharmaceuticals
  • AstraZeneca
  • Bharat Pharmaceuticals
  • Cempra
  • Debiopharm Group
  • GlaxoSmithKline
  • MORE
New Report Released: - Global Gonorrhea Therapeutics Market 2017-2021

The author of the report recognizes the following companies as the key players in the global gonorrhea therapeutics market: Bharat Pharmaceuticals, GlaxoSmithKline, Merck, and Pfizer

Other Prominent Vendors in the market are: Alopexx Pharmaceuticals, AstraZeneca, Cempra, Debiopharm Group, and Melinta Therapeutics.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Advent of vaccine for prevention of gonorrhea . Gonorrhea is a major public health concern globally. It is considerably affecting the reproductive health of people and increasing the spread of human immunodeficiency virus (HIV). The currently available treatment regimen is unsuccessful in controlling the spread of Neisseria gonorrhoeae due to the rapid emergence of the antibiotic-resistant strains of this bacterium. Therefore, the prevention of the disease seems to be a more appropriate approach for controlling the spread of Neisseria gonorrhoeae.”

According to the report, one of the major drivers for this market is Rising prevalence of disease. The rising prevalence of gonorrhea is a major health concern globally. As per the CDC, approximately 700,000 new cases of gonorrhea are identified each year in the US. In 2009, the CDC reported 301,174 cases of gonorrhea, demonstrating an incidence rate of 99.1 cases per 100,000 US population. The disease follows chlamydial infection as the second most common STD in the US. The rising prevalence rate of gonorrhea is due to several factors such as growing awareness, increased healthcare access, availability of diagnostic tests, resistance patterns, reporting practices, and the financial constraints that limit the abilities of public healthcare officials to check the disease pattern precisely.

Further, the report states that one of the major factors hindering the growth of this market is Emergence of antibiotic-resistant gonococcal strain. The global gonorrhea therapeutics market is familiar with antibiotic resistance in gonorrheal strains. In 2007, the emergence of fluoroquinolone-resistant Neisseria gonorrhoeae prompted the CDC to prohibit the use of fluoroquinolone in the US, leaving cephalosporin as the only treatment option for gonorrheal infection. However, during 2006-2011, the minimum inhibitory concentration (MIC) of cefixime increased in the US and other countries, indicating the decrease in effectiveness of cefixime for treating the gonorrheal infection. In addition, these cefixime-resistant gonococcal strains are likely to develop tetracycline resistance but are susceptible to azithromycin.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Bharat Pharmaceuticals
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Alopexx Pharmaceuticals
  • AstraZeneca
  • Cempra
  • Debiopharm Group
  • Melinta Therapeutics
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll